KCM
TWST icon

KRS Capital Management’s Twist Bioscience TWST Stock Holding History

KRS Capital Management’s Portfolio TWST Stock Details TWST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-600
Closed -$46K – 341
2021
Q4 		$46K Buy
+600
New +$61.6K 0.04% 237

Other funds holding TWST

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

KRS Capital Management's TWST Position: Q1 2022 in Review

KRS Capital Management sold out of Twist Bioscience (TWST) in Q1 2022, closing a stake of 600 shares — an estimated $46K sold.

KRS Capital Management first reported a position in TWST in Q4 2021 and held it in 1 quarter. The position peaked at $46K in Q4 2021. 212 funds tracked by Wall St. Rank hold TWST as of Q1 2022.

  • KRS Capital Management reported no remaining Twist Bioscience position as of Q1 2022 after selling out during the quarter.
  • KRS Capital Management sold 600 Twist Bioscience shares in Q1 2022, an estimated $46K.
  • KRS Capital Management first reported a position in Twist Bioscience in Q4 2021 and held it in 1 quarter.
  • KRS Capital Management's Twist Bioscience position peaked at $46K in Q4 2021.
  • 212 funds tracked by Wall St. Rank held Twist Bioscience as of Q1 2022.

Based on KRS Capital Management's 13F filing for Q1 2022, filed 27 Apr 2022.